PepGen (PEPG) Capital Expenditures (2021 - 2026)
PepGen (PEPG) posted Capital Expenditures of -$1000.0 for Q4 2025, down 101.03% sequentially from $97000.0 in Q3 2025, and down 100.44% YoY from $228000.0 in Q4 2024.
Analysis
PepGen (PEPG) Capital Expenditures (2021 - 2026) Analysis & Trends
PepGen has reported Capital Expenditures for 5 years, with the latest figure at -$1000.0 in Q4 2025.
- Quarterly Capital Expenditures fell 100.44% year-over-year to -$1000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $139000.0 (down 75.57% YoY) and the FY2025 annual result came in at $264000.0, down 46.88% from the prior year.
- Capital Expenditures slipped to -$1000.0 in Q4 2025 per PEPG's latest filing, from $97000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $1.6 million in Q1 2022 and troughed at -$1000.0 in Q4 2025.
- A 5-year average of $380750.0 and a median of $184500.0 in 2023 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2025: Capital Expenditures soared 3960.0% in 2022, then tumbled 100.44% in 2025.
- Over 5 years, Capital Expenditures stood at $156000.0 in 2021, then surged by 606.41% to $1.1 million in 2022, then sank by 83.3% to $184000.0 in 2023, then advanced by 23.91% to $228000.0 in 2024, then slumped by 100.44% to -$1000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$1000.0, $97000.0, and $43000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | 30,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | 97,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Mar 31, 2025 | 125,000.00 |
| Dec 31, 2024 | 228,000.00 |
| Sep 30, 2024 | 185,000.00 |
| Jun 30, 2024 | 31,000.00 |
| Mar 31, 2024 | 53,000.00 |
| Dec 31, 2023 | 184,000.00 |
| Sep 30, 2023 | 225,000.00 |
| Jun 30, 2023 | 1.01 Mn |
| Mar 31, 2023 | 1.18 Mn |
| Dec 31, 2022 | 1.10 Mn |
| Sep 30, 2022 | 430,000.00 |
| Jun 30, 2022 | 609,000.00 |
| Mar 31, 2022 | 1.61 Mn |
| Dec 31, 2021 | 156,000.00 |
| Sep 30, 2021 | 24,000.00 |
| Jun 30, 2021 | 15,000.00 |